Cargando…
Omapatrilat, an Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibitor, Attenuates Early Atherosclerosis in Diabetic and in Nondiabetic Low-Density Lipoprotein Receptor–Deficient Mice
Omapatrilat inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). ACE inhibitors have been shown to inhibit atherosclerosis in apoE-deficient mice and in several other animal models but failed in low-density lipoprotein (LDL) receptor– deficient mice despite effective in...
Autores principales: | Levy, Zohar, Dvir, Ayana, Shaish, Aviv, Trestman, Svetlana, Cohen, Hofit, Levkovietz, Hana, Rhachmani, Rita, Ravid, Mordchai, Harats, Dror |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480500/ https://www.ncbi.nlm.nih.gov/pubmed/12745671 http://dx.doi.org/10.1080/15438600303728 |
Ejemplares similares
-
Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?
por: Bitzur, Rafael, et al.
Publicado: (2009) -
Should All Diabetic Patients Be Treated With a Statin?
por: Kamari, Yehuda, et al.
Publicado: (2009) -
Molecular Basis
for Omapatrilat and Sampatrilat Binding
to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting
Enzyme
por: Sharma, Urvashi, et al.
Publicado: (2020) -
Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins
por: Boehm-Cagan, Anat, et al.
Publicado: (2016) -
Dietary β-Carotene Rescues Vitamin A Deficiency and Inhibits Atherogenesis in Apolipoprotein E-Deficient Mice
por: Harari, Ayelet, et al.
Publicado: (2020)